New Delhi, Aug 17 (IANS) A total of 7.37 crore hospital admissions worth Rs 1 lakh crore have been authorised under the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) as of June 30, 2024, according to the latest data compiled by the Ministry of Health.
The scheme has been implemented in 33 states/UTs.
The leading states in which Ayushman cards have been created under the PMJAY scheme include Madhya Pradesh with 402.5 lakh cards, Maharashtra (280 lakh), Karnataka (171.5 lakh) Jammu and Kashmir (85.9 lakh), Telangana (82.5 lakh), Tamil Nadu (73.6 lakh) and Meghalaya (19.76 lakh).
Beneficiaries eligible under the scheme can create their Ayushman card at any time throughout the year.
Eligible beneficiaries can either create the card themselves using Ayushman App or visit the nearest CSC or empanelled hospital to create their Ayushman card.
AB-PMJAY aims to provide health cover of Rs 5 lakh per family per year for secondary and tertiary care hospitalisation to approximately 55 crore beneficiaries corresponding to 12.34 crore families constituting the bottom 40 per cent of India’s population, according to official data.
Eligible beneficiaries can avail of cashless and paperless healthcare services related to hospitalisation across more than 29,000 empanelled hospitals in the country.
The cashless treatment covers all the costs related to treatment, medicines, supplies, diagnostic services, physician’s fees, room charges, surgeon charges, OT & ICU charges, etc.
The top speciality care treatments availed by beneficiaries to date are general medicine, infectious diseases, general surgery, medical oncology, ophthalmology and orthopaedics, according to the Health Ministry.
In the latest national master of the Health Benefit Package (HBP), the scheme provides cashless healthcare services related to 1,949 procedures across 27 medical specialties including General Medicine, Surgery, Cardiology, Oncology, etc.
Among the procedures availed by the people, are hemodialysis, screening for Covid-19, multiple packages and acute febrile illness.
The allocations for the PMJAY scheme in the Budget for 2024-25 allocation has been increased by 10 per cent to ₹7,300 crore from the revised estimate of ₹6,800 crore in 2023-24.
Overall the allocation to the Health Ministry in the budget has been raised by 12.96 per cent to ₹90,958.63 crore compared to ₹80,517.62 crore in the revised estimate for 2023-24.
As part of the healthcare package in the Budget, the government has also announced customs duty exemptions on three cancer treatment drugs — Trastuzumab Deruxtecan, Osimertinib and Durvalumab. The move is aimed at reducing the cost of treatment for cancer patients.
–IANS
sps/rad
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
